Relugolix As a Promising Novel Oral GnRH Antagonist for Prostate Cancer Treatment

Jidong Lv,Jianqing Lin

DOI: https://doi.org/10.4103/aja.aja_77_20

2021-01-01

Abstract:Currently, degarelix is the only LHRH antagonist, while there are a few LHRH agonists in the USA market. These include leuprolide (in the formula of Eligard, Lupron Depot, etc.); goserelin (Zoladex); triptorelin (Trelstar); and histrelin (Vantas). Compared to LHRH agonists, degarelix has a pharmacological profile more closely matching orchiectomy, with an immediate onset of action and faster testosterone and prostate-specific antigen suppression, without a testosterone surge or microsurges. As a consequence, with this GnRH blocker, there is no risk of clinical flare and no need for concomitant antiandrogen flare protection. In addition to this pharmacodynamic advantage, degarelix likely has less cardiovascular side effects than LHRH agonist. A prospective Phase IIIb trial (PRONOUNCE, ClinicalTrials. gov NCT02663908) designed to compare the occurrence of MACE in patients with advanced prostate cancer and preexisting atherosclerotic cardiovascular disease receiving either a degarelix or a GnRH agonist (leuprolide) as ADT for 12 months was launched but on hold now after a feasibility analysis. However, pooled data from six Phase III prospective randomized trials that recruited 2328 men between 2005 and 2012 showed that among men with preexisting cardiovascular disease, the risk of cardiovascular events within 1 year of initiating therapy was significantly lower among men treated with a GnRH antagonist compared with those treated with a GnRH agonist (hazard ratio: 0.44; 95% confidence interval: 0.26–0.74; P = 0.002).2 Overall, these cardiovascular adverse event data of degarelix match well with that of relugolix based on a recent study (Table 1). Despite the advantages mentioned above, compared to LHRH agonist, degarelix is still less utilized probably due to the injectionC androgen deprivation therapy (ADT) is the mainstay of treatment for metastatic prostate cancer. Both injectable luteinizing hormone– releasing hormone (LHRH) agonists and antagonists (here LHRH interchangeable to gonadotropin-releasing hormone, GnRH) are the current standard of care for ADT in prostate cancer. The novel oral form of effective GnRH antagonist is a very promising alternative to the current landscape of ADT. Most re cent ly, a Phas e I I I t r i a l comparing oral GnRH antagonist relugolix (120 mg orally once daily) with leuprolide (injections every 3 months) in advanced prostate cancer was completed and published.1 The primary objective of the study was to compare the ability of these agents’ sustained testosterone suppression to castrate levels (<50 ng dl−1) through a 48week study period. Relugolix achieved rapid (compatible to another GnRH antagonist degarelix) castration level of testosterone that was superior to that with leuprolide, also very importantly, with a 54% lower risk of major adverse cardiovascular events (MACEs). Other side effects of relugolix were mild and expected. With final approval pending from regulatory agencies, this oral agent could be favored by both providers and patients and represent a very promising addition to the current prostate cancer treatment landscape. Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment